Plasma Glucagon-like Peptide-1 Levels and Acute Myocardial Infarction

October 3, 2017 updated by: Li Jing Wei, Chinese PLA General Hospital

Prognostic Value of Plasma Glucagon-like Peptide-1 Levels in Acute Myocardial Infarction

GLP-1(9-36) amide and (9-37), which was previously thought to be the inactive metabolite of GLP-1, also exerts cardioprotective effects. Direct administration of GLP-1(9-36) during reperfusion reduced ischaemic damage in isolated hearts and increased cGMP release, vasodilatation and coronary flow in AMI mouse model, one may speculate that total GLP-1 level may associate with adverse cardiovascular events in AMI patients, the hypothesis is therefore tested in this study.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

709

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

A single center study on PCI-treated myocardial infarction patients

Description

Inclusion Criteria:

  • consecutive patients of acute AMI come to our department,absent of cardiogenic shock, and survival for at least 24 h after PCI treatment.

Exclusion Criteria:

  • patients with cancer, and patients who were taking a DPP4 inhibitor or a glucagon-like peptide-1 (GLP-1) analogue

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
all-cause mortality
Time Frame: The median follow-up was 29 months
The median follow-up was 29 months
cardiovascular mortality
Time Frame: The median follow-up was 29 months
The median follow-up was 29 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
non-cardiovascular mortality
Time Frame: The median follow-up was 29 months
The median follow-up was 29 months
Myocardial infarction
Time Frame: The median follow-up was 29 months
The median follow-up was 29 months
heart failure readmission
Time Frame: The median follow-up was 29 months
readmission to any hospital due to diagnosed heart failure
The median follow-up was 29 months
Stroke
Time Frame: The median follow-up was 29 months
defined using the World Health Organization criteria
The median follow-up was 29 months
repeated revascularization
Time Frame: The median follow-up was 29 months
defined as repeated PCI or bypass grafting of not only infarct related artery
The median follow-up was 29 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chinese PLA General Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2013

Primary Completion (Actual)

February 1, 2015

Study Completion (Actual)

February 1, 2015

Study Registration Dates

First Submitted

April 23, 2017

First Submitted That Met QC Criteria

April 25, 2017

First Posted (Actual)

April 26, 2017

Study Record Updates

Last Update Posted (Actual)

October 4, 2017

Last Update Submitted That Met QC Criteria

October 3, 2017

Last Verified

October 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GLP1AMI

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Angiography

Clinical Trials on plasma glucagon-like peptide-1 levels

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe